Comprehensive Stock Comparison
Compare Caris Life Sciences, Inc. (CAI) vs BiomX Inc. (PHGE) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Stability / Safety |  PHGE | Beta 0.93 vs CAI's 1.09 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) |  CAI | -29.1% vs PHGE's -48.8% |
| Efficiency (ROA) | CAI | -47.8% ROA vs PHGE's -142.8% |
Who Each Stock Is For
Income & stability
PHGEbeta 0.93
Growth exposure
PHGEEPS growth 71.2%
Long-term compounding (10Y)
CAI-29.1% 10Y total return vs PHGE's -99.7%
Sleep-well-at-night portfolio
CAILower volatility, beta 1.09, Low D/E 0.0%, current ratio 7.85x
Defensive / Recession hedge
PHGEBeta 0.93, current ratio 2.48x
Business Model
What each company does and how it makes money
Caris Life Sciences is an AI-powered molecular diagnostics company that provides comprehensive cancer profiling services to guide treatment decisions. It generates revenue primarily from molecular testing services for oncology patients — including tissue-based and blood-based profiling — along with pharmaceutical research services for drug development partners. The company's competitive advantage lies in its extensive molecular database and proprietary AI algorithms that analyze complex biomarker data to deliver personalized cancer treatment insights.
BiomX is a clinical-stage biotechnology company developing targeted phage therapies — viruses that kill specific harmful bacteria — for chronic diseases and skin conditions. It generates no commercial revenue yet but is funded through equity offerings and partnerships to advance its pipeline, which includes therapies for cystic fibrosis, inflammatory bowel diseases, and atopic dermatitis. The company's key advantage is its proprietary platform for discovering and engineering natural phages that precisely target disease-causing bacteria while sparing beneficial microbes.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
CAI 3PHGE 0CAI2/2 metricsCAI8/8 metricsCAI5/6 metricsCAI leads in 3 of 6 categories — strongest in Valuation Metrics and Profitability & Efficiency. 1 category is tied.
Financial Metrics (TTM)
CAI and PHGE operate at a comparable scale, with $812M and $0 in trailing revenue.
| Metric | CAICaris Life Scienc… | PHGEBiomX Inc. |
|---|---|---|
| RevenueTrailing 12 months | $812M | $0 |
| EBITDAEarnings before interest/tax | $70M | -$6M |
| Net IncomeAfter-tax profit | -$538M | -$37M |
| Free Cash FlowCash after capex | $33M | -$28M |
| Gross MarginGross profit ÷ Revenue | +46.2% | — |
| Operating MarginEBIT ÷ Revenue | +5.6% | — |
| Net MarginNet income ÷ Revenue | -66.2% | — |
| FCF MarginFCF ÷ Revenue | +4.0% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | — | -6.5% |
Valuation Metrics
| Metric | CAICaris Life Scienc… | PHGEBiomX Inc. |
|---|---|---|
| Market CapShares × price | $33.2B | $82.8B |
| Enterprise ValueMkt cap + debt − cash | $32.4B | $82.8B |
| Trailing P/EPrice ÷ TTM EPS | -6.17x | -4.29x |
| Forward P/EPrice ÷ next-FY EPS est. | 62.06x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 718.40x | — |
| Price / SalesMarket cap ÷ Revenue | 40.89x | — |
| Price / BookPrice ÷ Book value/share | 57.52x | 3427.64x |
| Price / FCFMarket cap ÷ FCF | 496.41x | — |
Profitability & Efficiency
CAI delivers a -93.2% return on equity — every $100 of shareholder capital generates $-93 in annual profit, vs $-4 for PHGE. CAI carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to PHGE's 0.40x. On the Piotroski fundamental quality scale (0–9), CAI scores 5/9 vs PHGE's 3/9, reflecting solid financial health.
| Metric | CAICaris Life Scienc… | PHGEBiomX Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -93.2% | -3.6% |
| ROA (TTM)Return on assets | -47.8% | -142.8% |
| ROICReturn on invested capital | — | -3.1% |
| ROCEReturn on capital employed | +7.7% | -159.9% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 3 |
| Debt / EquityFinancial leverage | 0.00x | 0.40x |
| Net DebtTotal debt minus cash | -$798M | -$8M |
| Cash & Equiv.Liquid assets | $798M | $18M |
| Total DebtShort + long-term debt | $169,000 | $10M |
| Interest CoverageEBIT ÷ Interest expense | -2.23x | -36.86x |
Total Returns (with DRIP)
A $10,000 investment in CAI five years ago would be worth $7,093 today (with dividends reinvested), compared to $47 for PHGE. Over the past 12 months, CAI leads with a -29.1% total return vs PHGE's -48.8%. The 3-year compound annual growth rate (CAGR) favors CAI at -10.8% vs PHGE's -59.1% — a key indicator of consistent wealth creation.
| Metric | CAICaris Life Scienc… | PHGEBiomX Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -26.4% | +194.4% |
| 1-Year ReturnPast 12 months | -29.1% | -48.8% |
| 3-Year ReturnCumulative with dividends | -29.1% | -93.2% |
| 5-Year ReturnCumulative with dividends | -29.1% | -99.5% |
| 10-Year ReturnCumulative with dividends | -29.1% | -99.7% |
| CAGR (3Y)Annualised 3-year return | -10.8% | -59.1% |
Risk & Volatility
PHGE is the less volatile stock with a 0.93 beta — it tends to amplify market swings less than CAI's 1.09 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CAI currently trades 46.7% from its 52-week high vs PHGE's 42.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CAICaris Life Scienc… | PHGEBiomX Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.09x | 0.93x |
| 52-Week HighHighest price in past year | $42.50 | $14.71 |
| 52-Week LowLowest price in past year | $17.15 | $1.56 |
| % of 52W HighCurrent price vs 52-week peak | +46.7% | +42.8% |
| RSI (14)Momentum oscillator 0–100 | 38.4 | 51.0 |
| Avg Volume (50D)Average daily shares traded | 2.3M | 1.3M |
Analyst Outlook
| Metric | CAICaris Life Scienc… | PHGEBiomX Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — |
| Price TargetConsensus 12-month target | $31.33 | — |
| # AnalystsCovering analysts | 6 | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 4 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Caris Life Sciences… (CAI) | $294M | $812M | +175.9% |
| BiomX Inc. (PHGE) | $0.00 | $0.00 | — |
Caris Life Sciences, Inc.'s revenue grew from $294M (2016) to $812M (2025) — a 11.9% CAGR.
Chart 2EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Caris Life Sciences… (CAI) | 0.31 | -3.22 | -1138.7% |
| BiomX Inc. (PHGE) | -3.27 | -1.47 | +55.0% |
Caris Life Sciences, Inc.'s EPS grew from $0.31 (2016) to $-3.22 (2025) — a NaN% CAGR.
Chart 3Free Cash Flow — 5 Years
Caris Life Sciences, Inc. generated $67M FCF in 2025 (+120% vs 2022). BiomX Inc. generated $-37M FCF in 2024 (-18% vs 2021).
CAI vs PHGE: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is CAI or PHGE a better buy right now?
Analysts rate Caris Life Sciences, Inc. (CAI) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CAI or PHGE?
Over the past 5 years, Caris Life Sciences, Inc. (CAI) delivered a total return of -29.1%, compared to -99.5% for BiomX Inc. (PHGE). A $10,000 investment in CAI five years ago would be worth approximately $7K today (assuming dividends reinvested). Over 10 years, the gap is even starker: CAI returned -29.1% versus PHGE's -99.7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CAI or PHGE?
By beta (market sensitivity over 5 years), BiomX Inc. (PHGE) is the lower-risk stock at 0.93β versus Caris Life Sciences, Inc.'s 1.09β — meaning CAI is approximately 18% more volatile than PHGE relative to the S&P 500. On balance sheet safety, Caris Life Sciences, Inc. (CAI) carries a lower debt/equity ratio of 0% versus 40% for BiomX Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — CAI or PHGE?
BiomX Inc. (PHGE) is the more profitable company, earning 0.0% net margin versus -66.2% for Caris Life Sciences, Inc. — meaning it keeps 0.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CAI leads at 5.6% versus 0.0% for PHGE. At the gross margin level — before operating expenses — CAI leads at 46.2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — CAI or PHGE?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is CAI or PHGE better for a retirement portfolio?
For long-horizon retirement investors, BiomX Inc. (PHGE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.93)). Both have compounded well over 10 years (PHGE: -99.7%, CAI: -29.1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between CAI and PHGE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.